Polycythemia vera (PV): A certain subset of patients will pose challenges
Dr Spivak published a study in the New England Journal of Medicine in which he described the identification of a subset of patients with aggressive, high-risk polycythemia vera. Incyte Corporation has partnered with Dr Jerry L. Spivak—a highly regarded expert in chronic myeloproliferative disorders—to discuss the phenotypic variability of polycythemia vera (PV), the need for identification and early institution of therapy for the subset of patients who may be at risk for a more aggressive disease course, and the data surrounding gene expression profiling as a clinical assessment to help inform future patient identification analyses and risk management. Insights from this collaboration can be found on PVStateofMind.com. Brought to you by Incyte Corporation © 2016, Incyte Corporation. All rights reserved. EDU-1380 07/16
